Literature DB >> 19005756

Argon plasma coagulation versus endoscopic mucosal resection in patients with dysplastic Barrett's esophagus.

Jaume Boix, Vicente Lorenzo-Zúñiga, Vicente Moreno de Vega, Ramón Planas.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19005756     DOI: 10.1007/s10620-008-0546-x

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  5 in total

1.  Ablation of nonneoplastic Barrett's mucosa using argon plasma coagulation with concomitant esomeprazole therapy (APBANEX): a prospective multicenter evaluation.

Authors:  Hendrik Manner; Andrea May; Stephan Miehlke; Stephan Dertinger; Bernd Wigginghaus; Wolfgang Schimming; Walter Krämer; Gabriele Niemann; Manfred Stolte; Christian Ell
Journal:  Am J Gastroenterol       Date:  2006-06-30       Impact factor: 10.864

2.  Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus.

Authors:  C Ell; A May; L Gossner; O Pech; E Günter; G Mayer; R Henrich; M Vieth; H Müller; G Seitz; M Stolte
Journal:  Gastroenterology       Date:  2000-04       Impact factor: 22.682

3.  The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence.

Authors:  Heiko Pohl; H Gilbert Welch
Journal:  J Natl Cancer Inst       Date:  2005-01-19       Impact factor: 13.506

4.  Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus.

Authors:  Hashem B El-Serag; Thomas V Aguirre; Stephanie Davis; Mark Kuebeler; Achyut Bhattacharyya; Richard E Sampliner
Journal:  Am J Gastroenterol       Date:  2004-10       Impact factor: 10.864

5.  5-aminolevulinic acid photodynamic therapy versus argon plasma coagulation for ablation of Barrett's oesophagus: a randomised trial.

Authors:  M Hage; P D Siersema; H van Dekken; E W Steyerberg; J Haringsma; W van de Vrie; T E Grool; R L P van Veen; H J C M Sterenborg; E J Kuipers
Journal:  Gut       Date:  2004-06       Impact factor: 23.059

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.